Skip to content

PressReach

SEARCH icon
  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos
Search

SEARCH FOR AN ARTICLE

  • Investing
  • Featured
  • Market
  • Biotech
  • Oil & Gas
  • Mining
  • Gaming
  • Tech
  • Crypto
  • More
    • Health
    • Entertainment
    • Real Estate
    • Cannabis
    • ESG
    • Financial
    • Food & Beverage
    • Industrials
    • Travel & Hospitality
    • Trading Tips
    • Investing Videos

PressReach

icon

      HomeBiotech

      Biotech

      FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
      Biotech

      FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

      August 19, 2022
      SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022
      Biotech

      SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022

      August 19, 2022
      BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
      Biotech

      BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

      August 18, 2022
      NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results
      Biotech

      NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results

      August 18, 2022
      Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
      Biotech

      Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      August 18, 2022
      Day One Reports Second Quarter 2022 Financial Results and Corporate Progress
      Biotech

      Day One Reports Second Quarter 2022 Financial Results and Corporate Progress

      August 18, 2022
      BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia
      Biotech

      BioCryst Announces Approval of ORLADEYO® (berotralstat) in Saudi Arabia

      August 18, 2022
      Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
      Biotech

      Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum

      August 18, 2022
      Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344
      Biotech

      Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

      August 9, 2022
      Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
      Biotech

      Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

      August 9, 2022
      « 1 … 124 125 126 127 128 … 140 »

       

      LATEST NEWS

      • Health Sanofi Market Potential Boosted by Amvuttra Data

      PressReach

      All logos, trade names and/or trademarks, artwork and associated imagery are trademarks and/or copyright material of their respective owners.

      • Advertisers
      • Privacy Policy
      • Terms of Use
      • DMCA Policy
      • Disclaimer
      • Contact Us

      SUBSCRIBE

      To get email updates from PressReach.

      I want e-mail alerts, updates, and offers and agree to the PressReach privacy policy.

      Market Jar Media Inc. © 2026